Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Erasca, Inc. ERAS
$2.86
-$0.15 (-5.15%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
459296426.00000000
-
week52high
10.74
-
week52low
2.49
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.00000000
-
EPS
-1.92000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 04:00
Описание компании
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | 10 авг 2021 г. | |
| JP Morgan | Overweight | 10 авг 2021 г. | |
| Guggenheim | Buy | 10 авг 2021 г. | |
| Evercore ISI Group | Outperform | 10 авг 2021 г. | |
| B of A Securities | Buy | 10 авг 2021 г. | |
| Morgan Stanley | Overweight | Equal-Weight | 03 февр 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Lim Jonathan E | A | 1500000 | 1500000 | 01 февр 2023 г. |
| Garner Ebun | A | 480000 | 480000 | 01 февр 2023 г. |
| Garner Ebun | A | 4280 | 2 | 01 февр 2023 г. |
| Wei Lin | A | 560000 | 560000 | 01 февр 2023 г. |
| Wei Lin | A | 315812 | 2 | 01 февр 2023 г. |
| Chacko David M. | A | 600000 | 600000 | 01 февр 2023 г. |
| Chacko David M. | A | 239248 | 2 | 01 февр 2023 г. |
| Lim Jonathan E | A | 20256222 | 60000 | 10 янв 2023 г. |
| Bristol James Arthur | A | 20000 | 20000 | 21 дек 2022 г. |
| Start Valerie Denise Harding | A | 10000 | 10000 | 21 дек 2022 г. |
Новостная лента
MDA Breakout Stocks Week 6 - February 2023: High-Frequency Gainers To Give You An Edge
Seeking Alpha
06 февр 2023 г. в 08:01
Two new Breakout Stocks for Week 6 with better than 10% short-term upside and two Dow 30 Picks. Average cumulative returns for 2023 are +28.2% YTD. This week 3 of 4 high-frequency breakout picks gained over 10% in less than a week with peak gains in TOUR +20.3%, RIVN +12.8%, JMIA +22.1%.
Erasca to Present at the Guggenheim Oncology Conference 2023
GlobeNewsWire
01 февр 2023 г. в 08:00
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Oncology Conference 2023. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a fireside chat beginning at 1:00 pm Eastern Time on Wednesday, February 8, 2023. Drs. Lim and Chacko will also participate in one-on-one investor meetings.
Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
04 янв 2023 г. в 08:00
SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 41st annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California. Jonathan E. Lim, M.D., chairman, CEO, and co-founder will present an overview of the company and its pipeline at 8:15 am Pacific Time on Monday, January 9, 2023, in Elizabethan Room C. Dr. Lim and David M. Chacko, M.D., chief financial officer, will also participate in one-on-one investor meetings.
Erasca to Present at the Bank of America Securities Precision Oncology Conference 2022
GlobeNewsWire
26 сент 2022 г. в 08:00
SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities Precision Oncology Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a virtual fireside chat at 3:40 pm Eastern Time on Monday, October 3, 2022. Drs. Lim and Chacko will also participate in one-on-one investor meetings.
Erasca to Present at the Morgan Stanley Global Healthcare Conference
GlobeNewsWire
09 сент 2022 г. в 08:31
SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley Global Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a fireside chat at 12:55 pm Eastern Time on Wednesday, September 14, 2022, at the Sheraton Hotel in New York, New York. Drs. Lim and Chacko will also participate in one-on-one investor meetings.